Trials / Conditions / Esophagogastric Junction Disorder

Esophagogastric Junction Disorder

8 registered clinical trials studyying Esophagogastric Junction Disorder — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction NCT04938102	University of Kansas Medical Center	N/A
Withdrawn	Idiopathic Esophagogastric Junction Outflow Obstruction NCT04096703	Wake Forest University Health Sciences	N/A
Terminated	Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer NCT05161572	Fudan University	Phase 2
Active Not Recruiting	Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients NCT04923932	Hutchison Medipharma Limited	Phase 2
Recruiting	CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1 NCT04455282	Heinrich-Heine University, Duesseldorf	—
Not Yet Recruiting	Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma NCT03961841	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 3
Unknown	Severe Complications After Gastrectomy for Esophagogastric Junction and Gastric Cancer NCT03909997	Hospital Dr Sotero del Rio	—
Completed	Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction NCT03549494	Catalysis SL	Phase 2